SequelSEC

NEUROCRINE BIOSCIENCES INC NBIX

Biological Products, (No Diagnostic Substances) · CIK 0000914475 · Fiscal year ends 1231

Revenue
$2.86B
Fiscal year ended 2025-12-31
Operating income
$619.10M
Fiscal year ended 2025-12-31
Free cash flow
$748.70M
Fiscal year ended 2025-12-31

NEUROCRINE BIOSCIENCES INC (NBIX) reported revenue of $2.86B and net income of $478.60M for the fiscal year ended 2025-12-31. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from NEUROCRINE BIOSCIENCES INC’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).

Income

NEUROCRINE BIOSCIENCES INC income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Revenue$2.86B$2.36B$1.89B$1.49B$1.13B$1.05B$788.10M$451.20M$161.63M$15.00M
Cost of revenue$52.10M$34.00M$39.70M$23.20M$14.30M$10.10MUnavailable$4.89M$1.25M$0
Gross profit$2.81B$2.32B$1.85B$1.47B$1.12B$1.04BUnavailableUnavailableUnavailable$15.00M
Operating income$619.10M$570.50M$250.90M$249.00M$102.50M$163.00M$72.30M$36.80M-$131.36M-$147.37M
Net income$478.60M$341.30M$249.70M$154.50M$89.60M$407.30M$37.00M$21.10M-$142.54M-$141.09M
Research & developmentUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable$160.52M$121.83M$94.29M
Weighted-average diluted sharesshares 102.50Mshares 103.70Mshares 101.00Mshares 98.90Mshares 97.90Mshares 97.80Mshares 95.70Mshares 95.40Mshares 88.09Mshares 86.71M
Pretax income$705.40M$486.00M$332.10M$213.90M$101.40M$106.70M$46.50M$21.80M-$142.54M-$141.09M
Income tax expense$226.80M$144.70M$82.40M$59.40M$11.80M-$300.60M$9.50M$700.00K$0$0
Diluted EPS$4.67$3.29$2.47$1.56$0.92$4.16$0.39$0.22$-1.62$-1.63
Selling, general & administrative$1.16B$1.01B$887.60M$752.70M$583.30M$433.30M$354.10M$248.90M$169.91M$68.08M
General & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable$68.08M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

NEUROCRINE BIOSCIENCES INC balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Cash & equivalents$713.00M$233.00M$251.10M$262.90M$340.80M$187.10M$112.30M$141.71M$254.71M$83.27M
Total assets$4.63B$3.72B$3.25B$2.37B$2.07B$1.73B$1.31B$993.15M$817.59M$365.09M
Current assets$2.52B$1.72B$1.61B$1.45B$972.80M$1.02B$831.00M$737.78M$554.92M$310.44M
Total liabilities$1.38B$1.13B$1.02B$660.90M$698.50M$608.50M$669.10M$512.39M$445.45M$50.21M
Current liabilities$743.40M$507.70M$654.80M$537.70M$245.80M$186.50M$565.30M$88.23M$54.43M$30.41M
Total equity incl. NCI$3.25B$2.59B$2.23B$1.71B$1.37B$1.13B$636.90M$480.80M$372.20M$314.88M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Inventory$69.00M$57.40M$38.30M$35.10M$30.50M$28.00M$17.30M$10.86M$1.02M$0
Accounts receivable$686.80M$479.10M$439.30M$350.00M$185.50M$157.10M$126.60M$57.41M$31.13M$0
Goodwill$6.10M$5.70M$5.80M$5.40M$0UnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable$13.80M$5.65M$5.08M

Cash flow

NEUROCRINE BIOSCIENCES INC cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Operating cash flow$782.70M$595.40M$389.90M$339.40M$256.50M$228.50M$147.00M$101.40M-$94.33M-$106.18M
Capital expenditures$34.00M$38.20M$28.30M$16.50M$23.40M$10.90M$14.70M$24.80M$6.94M$4.11M
Investing cash flow-$264.40M-$126.80M-$467.10M-$177.10M-$130.20M$4.10M-$211.10M-$242.90M-$251.25M$112.96M
Financing cash flow-$38.30M-$486.70M$65.30M-$234.30M$27.40M-$157.80M$32.40M$29.50M$516.65M$2.39M
Net change in cash$480.00M-$18.10M-$11.60M-$73.30M$153.70M$74.80M-$31.70M-$112.00M$171.06M$9.16M
Stock-based compensation$217.90M$195.50M$194.30M$173.10M$134.20M$100.00M$75.30M$58.10M$42.52M$28.46M
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchases$167.70M$300.00M$0$0UnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable$4.02M$2.40M$1.45M

Derived

NEUROCRINE BIOSCIENCES INC derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Free cash flow$748.70M$557.20M$361.60M$322.90M$233.10M$217.60M$132.30M$76.60M-$101.27M-$110.29M
Gross margin98.2%98.6%97.9%98.4%98.7%99.0%UnavailableUnavailableUnavailable100.0%
Operating margin21.6%24.2%13.3%16.7%9.0%15.6%9.2%8.2%-81.3%-982.5%
FCF margin26.2%23.7%19.2%21.7%20.6%20.8%16.8%17.0%-62.7%-735.3%
SBC / revenue7.6%8.3%10.3%11.6%11.8%9.6%9.6%12.9%26.3%189.8%
Current ratio3.39x3.40x2.45x2.70x3.96x5.45x1.47x8.36x10.20x10.21x
Revenue YoY growth21.4%24.8%26.8%31.3%8.4%32.7%74.7%179.2%977.5%Unavailable
Net margin16.7%14.5%13.2%10.4%7.9%38.9%4.7%4.7%-88.2%-940.6%
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable628.6%
CapEx / revenue1.2%1.6%1.5%1.1%2.1%1.0%1.9%5.5%4.3%27.4%
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rate32.2%29.8%24.8%27.8%11.6%-281.7%20.4%3.2%UnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open NBIX in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-07-31View SEC filing
10-Q · Filed 2026-05-05View SEC filing
10-K · Filed 2026-02-11View SEC filing
10-Q · Filed 2025-10-28View SEC filing
10-Q · Filed 2025-07-30View SEC filing
10-Q · Filed 2025-05-05View SEC filing

Companies in the same industry

Reconciliation checks needing review

2 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

gross profit bridgeinconsistent2018-12-31

Withheld: gross profit could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2017-12-31

Withheld: gross profit could not be reconciled with the rest of this filer’s statement.